Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)
|ClinicalTrials.gov Identifier: NCT01288417|
Recruitment Status : Completed
First Posted : February 2, 2011
Last Update Posted : July 24, 2012
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||December 2011|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013 Jan;56(2):300-6. doi: 10.1093/cid/cis824. Epub 2012 Sep 21.